TrialThe oncologist2013

CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

Salomon M Stemmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.